SCHEMBL21638145

SCHEMBL21638145

COc1cc(C(=O)N2CCC(N3CCOCC3)CC2)ccc1Nc1cc(OC)c2c(C#N)c[nH]c2n1

nearest known ligand 0.67

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 9/20 0.67
▸ TTK P33981 1/20 0.66
▸ DYRK3 O43781 1/20 0.66
▸ CSNK1E P49674 1/20 0.66
▸ CLK1 P49759 1/20 0.66
▸ CLK2 P49760 1/20 0.66
▸ CLK3 P49761 1/20 0.66
▸ CLK4 Q9HAZ1 1/20 0.66
▸ DYRK1B Q9Y463 1/20 0.66
▸ LRRK2 Q5S007 9/20 0.55
▸ TYK2 P29597 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21638106 0.94 DYRK1A (0.65) DYRK1ATTKDYRK3CSNK1ECLK1
SCHEMBL21638144 0.94 TTK (0.69) DYRK1ATTKDYRK3CSNK1ECLK1
SCHEMBL21611018 0.93 DYRK1A (0.66) DYRK1ATTKDYRK3CSNK1ECLK1
SCHEMBL21738257 0.93 DYRK1A (0.64) DYRK1ATTKDYRK3CSNK1ECLK1
SCHEMBL29839409 0.91 DYRK1A (0.78) DYRK1ATTKDYRK3CSNK1ECLK1
SCHEMBL21611059 0.91 DYRK1A (0.78) DYRK1ATTKDYRK3CSNK1ECLK1
SCHEMBL21610996 0.90 DYRK1A (0.69) DYRK1ATTKDYRK3CSNK1ECLK1
SCHEMBL21611011 0.89 DYRK1A (0.69) DYRK1ATTKDYRK3CSNK1ECLK1
SCHEMBL21611051 0.89 TTK (0.55) DYRK1ATTKDYRK3CSNK1ECLK1
SCHEMBL21738219 0.88 TTK (0.69) DYRK1ATTKDYRK3CSNK1ECLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220106307-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2022-04-07 — — US claimed
US-11117892-B2 Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION 2021-09-14 — — US claimed
US-20200207756-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-07-02 — — US claimed
EP-3604304-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2020-02-05 — — EP claimed
US-20220106307-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2022-04-07 — — US disclosed
US-11117892-B2 Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION 2021-09-14 — — US disclosed
US-20200207756-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-07-02 — — US disclosed
EP-3604304-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2020-02-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106307-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DYRK1A, DYRK2, DYRK1B DYRK1A 1/4885TTK 100/4885DYRK3 4/4885
US-11117892-B2 Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases DYRK1A, DYRK2, DYRK1B DYRK1A 1/4885TTK 100/4885DYRK3 4/4885
US-20200207756-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DYRK1A, DYRK2, DYRK4 DYRK1A 1/4885TTK 93/4885DYRK3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback